Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is a small oligopeptide drug derived from angiotensin IV. It is currently being investigated for the treatment of Alzheimer’s disease and other neurological disorders.
Dihexa is thought to work by potentiating the activity of hepatocyte growth factor (HGF) at its receptor, c-Met. HGF is a potent neurotrophic factor that plays an important role in the development and maintenance of the nervous system. It also has neuroprotective and regenerative effects.
In animal studies, Dihexa has been shown to:
- Improve cognitive function
- Reduce amyloid beta plaques
- Promote the growth of new neurons in the hippocampus
- Protect neurons from damage
- Enhance nerve regeneration
- Improve blood flow to the brain
Based on these findings, Dihexa is being investigated for the following potential uses:
Alzheimer’s disease: Dihexa is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease. In a Phase 1 clinical trial, Dihexa was found to be safe and well-tolerated. In a Phase 2a clinical trial, Dihexa was shown to improve cognitive function and reduce amyloid beta plaques in patients with mild to moderate Alzheimer’s disease.
Other neurological disorders: Dihexa is also being investigated for the treatment of other neurological disorders, such as Parkinson’s disease, multiple sclerosis, and spinal cord injury. Preclinical studies have shown that Dihexa can improve cognitive function and protect neurons from damage in these disorders.
Cognitive impairment in cancer patients: Dihexa is also being investigated for the treatment of cognitive impairment in cancer patients who are undergoing chemotherapy. Chemotherapy can cause a number of side effects, including cognitive impairment. Dihexa is thought to be able to protect neurons from damage caused by chemotherapy and improve cognitive function in cancer patients.
Other potential uses: Dihexa is also being investigated for a number of other potential uses, including:
- Stroke
- Traumatic brain injury
- Depression
- Anxiety
- Pain
- Inflammation
Safety and side effects
Dihexa has been shown to be safe and well-tolerated in clinical trials. However, some people may experience side effects such as nausea, vomiting, diarrhea, and headache. Dihexa is not recommended for pregnant or breastfeeding women.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. It is a small molecule that can easily cross the blood-brain barrier and target HGF receptors in the brain. In animal studies, Dihexa has been shown to improve cognitive function, reduce amyloid beta plaques, promote the growth of new neurons, and protect neurons from damage. Dihexa is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease, and the results of these trials are eagerly awaited.
